CA3047621C - Cell expressing a car and a transcription factor and its use - Google Patents

Cell expressing a car and a transcription factor and its use Download PDF

Info

Publication number
CA3047621C
CA3047621C CA3047621A CA3047621A CA3047621C CA 3047621 C CA3047621 C CA 3047621C CA 3047621 A CA3047621 A CA 3047621A CA 3047621 A CA3047621 A CA 3047621A CA 3047621 C CA3047621 C CA 3047621C
Authority
CA
Canada
Prior art keywords
cell
cells
transcription factor
nucleic acid
car
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3047621A
Other languages
English (en)
French (fr)
Other versions
CA3047621A1 (en
Inventor
Martin Pule
Simon Thomas
Shaun CORDOBA
Wen Chean LIM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Autolus Ltd
Original Assignee
Autolus Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autolus Ltd filed Critical Autolus Ltd
Publication of CA3047621A1 publication Critical patent/CA3047621A1/en
Application granted granted Critical
Publication of CA3047621C publication Critical patent/CA3047621C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3047621A 2016-12-21 2017-12-20 Cell expressing a car and a transcription factor and its use Active CA3047621C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1621889.3 2016-12-21
GBGB1621889.3A GB201621889D0 (en) 2016-12-21 2016-12-21 Cell
PCT/GB2017/053834 WO2018115865A1 (en) 2016-12-21 2017-12-20 Cell expressing a car and a transcription factor and its use

Publications (2)

Publication Number Publication Date
CA3047621A1 CA3047621A1 (en) 2018-06-28
CA3047621C true CA3047621C (en) 2024-01-02

Family

ID=58284380

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3047621A Active CA3047621C (en) 2016-12-21 2017-12-20 Cell expressing a car and a transcription factor and its use

Country Status (8)

Country Link
US (2) US20200030379A1 (enExample)
EP (1) EP3559213A1 (enExample)
JP (5) JP7149273B2 (enExample)
CN (1) CN110099997A (enExample)
AU (1) AU2017380449B2 (enExample)
CA (1) CA3047621C (enExample)
GB (1) GB201621889D0 (enExample)
WO (1) WO2018115865A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220127570A1 (en) 2018-05-03 2022-04-28 Cafa Therapeutics Limited Immune effector cell and use thereof
US20210363217A1 (en) * 2018-06-19 2021-11-25 Autolus Limited Cell
EP3934666A1 (en) * 2019-03-08 2022-01-12 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
WO2022103789A1 (en) 2020-11-10 2022-05-19 Kyverna Therapeutics, Inc. A method for treating disease using foxp3+cd4+ t cells
CN114805596B (zh) * 2021-01-22 2023-07-14 华东师范大学 一种以磷脂酰肌醇聚糖3为靶点的嵌合抗原受体及其应用
WO2022164959A1 (en) 2021-01-27 2022-08-04 Lyell Immunopharma, Inc. Improved immune cell therapy
WO2022165419A1 (en) 2021-02-01 2022-08-04 Kyverna Therapeutics, Inc. Methods for increasing t-cell function
TW202246511A (zh) 2021-02-25 2022-12-01 美商萊爾免疫藥物股份有限公司 靶向ny-eso-1之增強免疫細胞療法
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
EP4298230A1 (en) 2021-02-25 2024-01-03 Lyell Immunopharma, Inc. Codon-optimized nucleotide sequences encoding an ap-1 transcription factor
KR20240027676A (ko) 2021-06-02 2024-03-04 라이엘 이뮤노파마, 인크. Nr4a3-결핍 면역 세포 및 이의 용도
US20230313138A1 (en) 2021-10-28 2023-10-05 Lyell Immunopharma, Inc. Methods for culturing cells expressing c-jun
JP2024540099A (ja) 2021-10-28 2024-10-31 ライエル・イミュノファーマ・インコーポレイテッド Ｒｏｒ１結合タンパク質を発現する細胞を培養する方法
EP4514363A4 (en) * 2022-04-25 2026-04-22 Univ Leland Stanford Junior COMPOSITIONS AND METHODS FOR PREVENTING T LYMPHOCYTE DEPLETION
US20260083846A1 (en) 2022-05-19 2026-03-26 Lyell Immunopharma, Inc. Polynucleotides targeting nr4a3 and uses thereof
WO2024020429A1 (en) 2022-07-22 2024-01-25 Lyell Immunopharma, Inc. Immune cell therapy
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2997134B1 (en) * 2013-05-14 2020-06-24 Board of Regents, The University of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
WO2016168595A1 (en) * 2015-04-17 2016-10-20 Barrett David Maxwell Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
GB201509413D0 (en) * 2015-06-01 2015-07-15 Ucl Business Plc Fusion protein
US11098283B2 (en) * 2015-08-25 2021-08-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cells modified to overexpress c-Myb
EP4166161B1 (en) * 2016-04-14 2026-03-04 Fred Hutchinson Cancer Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
WO2017190100A1 (en) * 2016-04-28 2017-11-02 The Trustees Of Dartmouth College Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof

Also Published As

Publication number Publication date
JP2024133287A (ja) 2024-10-01
US20200030379A1 (en) 2020-01-30
EP3559213A1 (en) 2019-10-30
JP2024133286A (ja) 2024-10-01
JP7874133B2 (ja) 2026-06-15
JP2020511115A (ja) 2020-04-16
GB201621889D0 (en) 2017-02-01
JP2026095705A (ja) 2026-06-11
AU2017380449B2 (en) 2023-01-05
WO2018115865A1 (en) 2018-06-28
AU2017380449A1 (en) 2019-06-13
CN110099997A (zh) 2019-08-06
CA3047621A1 (en) 2018-06-28
US20240307440A1 (en) 2024-09-19
JP2022145846A (ja) 2022-10-04
JP7149273B2 (ja) 2022-10-06

Similar Documents

Publication Publication Date Title
US20240307440A1 (en) Cell expressing a car and a transcription factor and its use
JP7460675B2 (ja) Ｐｄ－１－ｃｄ２８融合タンパク質および医療におけるその使用
JP7082046B2 (ja) 受容体
AU2017205637B2 (en) Compositions and libraries comprising recombinant T-cell receptors and methods of using recombinant T-cell receptors
EP3681995B1 (en) Cell
JP2017526361A (ja) シグナル伝達系
US20200338124A1 (en) Cell
JP7117304B2 (ja) 転写システム
CN106478809A (zh) 识别prame抗原短肽的tcr
CN115427440A (zh) 用于工程化细胞的嵌合受体
CN106749620A (zh) 识别mage‑a1抗原短肽的t细胞受体
WO2018229492A1 (en) Chimeric antigen receptor
CN109251243B (zh) 一种识别sage1抗原的t细胞受体及编码该受体的核酸
KR20240034205A (ko) 항EGFRviii 항체, 폴리펩타이드, 상기 폴리펩타이드를 발현하는 세포, 상기 세포를 포함하는 의약 조성물, 상기 세포의 제조 방법 및 상기 폴리펩타이드를 코딩하는 염기서열을 포함하는 폴리뉴클레오티드 또는 벡터
CN108929378B (zh) 一种识别prame抗原的t细胞受体及编码该受体的核酸
KR20240035506A (ko) 키메라 항원 수용체, 상기 수용체를 발현하는 세포, 상기 세포를 포함하는 의약 조성물, 상기 세포의 제조 방법, 및 상기 키메라 항원 수용체를 코딩하는 염기서열을 포함하는 폴리뉴클레오티드 또는 벡터
KR20240095172A (ko) 항원 특이적 t 세포 수용체 및 키메라 공동자극 수용체의 조합
EP3749351A1 (en) Polypeptides and methods

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20221123

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241210

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241210

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260203

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260804